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“Begin at the beginning,” the King said, very gravely, ‘and 
go on till you come to the end: Then stop.’ – Lewis Carroll, 
Alice in Wonderland
Pituitary incidentalomas (PIs) are generally described 
as sellar lesions without any overt features of pituitary 
disease that is found on brain imaging done for unrelated 
conditions.[1] After their initial description in 1936,[2] 
various studies have reported the prevalence of PI to be 
around 3–27% in autopsy series[3-5] and around 10% on 
diagnostic imaging.[6] 
However, despite their prevalence, limited information is 
available on the natural history of PI and many key questions 
remain unanswered. This article will briefly explore some 
of those questions and the associated inconsistencies.
The data from the autopsy studies showed that vast majority 
of PI were microadenomas (<10 mm), whereas those 
found on imaging typically tend to be macroadenomas 
(>10 mm). Our own study,[7] which was based on 
radiological imaging, showed that 71% of PI presented 
as macroadenomas, a trend supported by other studies.[8,9] 
This discrepancy is likely due to the imaging sequence 
as most PI are identified on imaging (magnetic resonance 
imaging or computed tomography) of the brain as opposed 
to the dedicated imaging of the sella.
Although PIs, by definition, are found on brain imaging 
done for unrelated conditions, the question remains if they 
are truly incidental lesions. Our own series[7] and another 
one from Japan[8] reported fairly similar indications 
for primary brain imaging, which included headache, 
dizziness, TIA/stroke, seizures and trauma. Headache 
has been associated with both small and large pituitary 
tumours[9] and can also occur in functioning pituitary 
tumours such as growth hormone-producing adenomas.
Furthermore, some PI on presentation may turn out to have 
previously undiagnosed visual field abnormalities.[7] In a 
recent analysis,[10] we found that PIs were around 20% 
more likely to present with previously undiagnosed visual 
field abnormalities than those who presented with clinical 
evidence of pituitary dysfunction. Can dizziness, which 
was a common indication for imaging, be associated with 
partial loss of vision in this group remains a tantalizing 
research question. As these associations become clearer, it 
would not be unreasonable to revisit the current definition 
of PI.
Although most PI tend to be either clinically non-
functioning pituitary adenomas or non-pituitary sellar 
masses, around 22% of all patients in our series[7] had 
previously undiagnosed functioning adenomas include 
prolactinomas (15%), growth hormone-producing 
adenomas (5%) and ACTH-producing adenoma (3%). 
Furthermore, most of these (>75%) were already 
macroadenomas at presentation. This is a surprising trend, 
as these tumours despite their size tend to be relatively 
hormonally quiescent. It remains to be determined why 
these tumours behave differently from their clinically 
manifesting counterparts. Data from other studies are 
rather conflicting; for instance, a large study from 
Japan following 506 patients[8] reported no clinical or 
biochemical evidence of hyperfunctioning tumours, 
whereas another series from Greece[11] reported 21% of 
patients had functioning tumours. Further studies looking 
at the pathophysiological characteristics of functioning 
PI versus clinically manifesting pituitary adenomas are 
needed. It is well described that most non-aggressive 
and slow-growing pituitary adenomas tend to be densely 
granulated adenomas as opposed to the sparsely granulated 
adenomas that are clinically and biochemically more 
aggressive.[12] It is currently unclear if functioning PIs 
are more likely to be densely granulated, and thus, as a 
result presents without overt clinical features of hormonal 
dysfunction. Similarly, studies on molecular genetics 
of these two entities are also required to identify key 
transcription factors that may explain their differential 
behaviour.
The risk of previously undiagnosed hormonal dysfunction 
is considerable in patients with PI. Indeed, our own 
data[7] showed that almost 30% of patients with PI had 
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biochemical evidence of hormonal loss at presentation 
including growth hormone deficiency, hypogonadism, 
secondary hypothyroidism, secondary hypoadrenalism 
and even diabetes insipidus. Although no study has 
formally compared the need for surgery in this group, 
our own analysis[10] showed that almost a third (32%) of 
PI eventually required surgical management as opposed 
to 46% of the clinically manifesting pituitary adenomas. 
Whether long-term outcomes of PI with or without 
treatment are different, remain to be studied. Future studies 
need to assess the rate of remission of incidental versus 
clinically manifesting pituitary tumours in response to 
medical and surgical therapy.
It is well established that larger and more aggressive 
functioning pituitary adenomas are less likely to achieve 
remission and where most PI present as macroadenomas, 
is the rate of remission similarly low? In addition, the 
pattern of response of functioning PI to the currently 
available pharmacologic therapies is another key area that 
needs to be explored. These are important considerations 
given that expert pituitary surgeons may not be available 
in certain areas; therefore, it is crucial to identify the most 
optimal treatment strategy for these growths.
Another area of uncertainty is the long-term rate of 
morbidity and mortality in functioning PI. The risk of 
morbidity and mortality is significantly high in clinically 
manifesting functioning tumours associated with 
acromegaly and Cushing’s disease. In addition, studies 
have reported a high risk of lingering psychological 
sequelae associated with these disorders even after 
achieving biochemical remission.[13,14] Given the relatively 
indolent presentation of these functioning PI, it is 
important to determine the risk of associated long-term 
complications, particularly risk of malignancy, sleep 
apnoea, hypertension and sexual dysfunction. These risks 
will help determine the targets for therapeutic intervention.
A familial predisposition of certain pituitary adenomas is 
being increasingly recognised. Is the risk of PI commoner 
in patients with known germline or somatic mutations 
are also an area that needs to be explored. One of the 
common mutations is a germline heterozygous mutation 
in the aryl hydrocarbon receptor-interacting protein[15] 
that is typically associated with large, invasive pituitary 
(mostly somatotropic or somatolactotropic) adenomas. 
Therefore, it is suggested that younger patients presenting 
with larger pituitary adenomas should undergo genetic 
testing. It would be crucial to identify such mutations in 
patients presenting with PI, which would eventually allow 
physicians to refine strategies for earlier testing.
In summary, PIs are frequently encountered in clinical 
practice and with a more widespread utility of sensitive 
imaging techniques; it is likely that the prevalence 
will continue to rise. Therefore, it is crucial to learn 
about the natural history of these lesions, to develop 
appropriate management paradigms. Furthermore, 
detailed histopathological, genetic and molecular studies 
are needed to understand the differences in characteristics 
at presentation and response to management therapies.
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